Alexion is a global biopharmaceutical company focused on bringing hope to patients and families affected by rare diseases and devastating conditions by delivering innovative, life-changing therapies. Alexion developed and commercializes two complement inhibitors – SOLIRIS® (eculizumab) and ULTOMIRIS® (ravulizumab) – to treat patients with atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), refractory generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). As the global leader in complement inhibition, Alexion is leveraging its experience in complement biology to pursue novel molecules and targets in the complement cascade.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since
1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases.
Asahi Kasei Medical
In Asahi Kasei’s medical enterprises, we have developed new medical devices and therapeutic technologies and made advances in biopharmaceutical and plasma derivative process engineering. We have achieved these through a high-level synergy of filtration and separation technologies using membranes, filters and adsorbents, together with wide-ranging knowledge and technological expertise in science, mechanical engineering and medical fields. Our filtration and separation technologies for blood and body fluids hold great promise as core technologies for integrative innovation.
Astellas is a pharmaceutical company committed to turning innovative science into value for patients. Changing tomorrow is the ethos that guides everything we do.
Across our areas of therapeutic expertise, we use our agility to match scientific breakthroughs to the unmet medical needs of people around the world, and the many healthcare professionals and caregivers who support them.
Astellas invests in new medicines, technologies and therapeutic areas, and builds partnerships and networks with others who share our vision to improve the future of medicine.
Astellas is working at the forefront of healthcare change and the values of patient focus, ownership, results, openness and integrity are the foundation of our culture.
AstraZeneca in CVRM
Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca’s three therapy areas and is a key growth driver for the Company. By following the science to understand the underlying links between the heart, kidneys and pancreas more clearly, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. The Company’s ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.
Aurinia Pharmaceuticals, Inc., is a fully integrated global biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. Aurinia is headquartered in Victoria, British Columbia and its U.S. commercial hub is located in Rockville, Maryland. In addition to driving the adoption of our approved therapy for lupus nephritis, we are actively pursuing a broader portfolio of innovative drugs.
A family-owned company founded in 1839 in Melsungen, Germany, B. Braun today is one of the world’s leading healthcare companies with more than 63,000 employees working in 64 countries. The product range includes dialysis machines and dialysis consumables for chronic dialysis, acute blood purification and apheresis. In addition to its role as a manufacturer of dialysis equipment, B. Braun is also an important provider of dialysis treatment. B. Braun operates more than 350 renal care centers. Additional care services such as holiday dialysis and pre-dialysis programs are offered in most markets, and B. Braun Avitum cooperates fully with local transplant organizations in different countries.
As a system partner, B. Braun does everything it can to understand its customers’ challenges so as to be able to work together with customer to design solutions which increase efficiency and add value along the entire patient pathway and customer value chain.
Baxter Healthcare SA
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.
To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world.
Are you looking for an easy, fast and accurate method to calculate Dry Weight? The NEW Multiscan 5000 is non-invasive and measures the Volume of Fluid Overload, as well as showing Body Composition, Hydration and BIVA Vector graph immediately on the colour touch screen. Since 1990, Bodystat has specialised in bio-impedance technology, spectroscopy and Cole Modelling. Raw data, Resistance, Reactance and Phase Angle are calculated at 50 frequencies up to 1000 kHz to help assess Dry Weight and to help assess nutritional status pre and post dialysis.
About Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance that centers on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the alliance. The Alliance leverages the strengths of two of the world’s leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical need. Clinical trials have been initiated to evaluate the impact of empagliflozin on people living with heart failure or chronic kidney disease.
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com/ and lilly.com/newsroom
Calliditas Therapeutics – developing, high-value products for patients with significant unmet medical needs. Primary immunoglobulin A nephropathy (IgAN) is a progressive, chronic disease that over time leads to kidney function deterioration. There are no approved treatments for IgAN. Calliditas Therapeutics’ lead pipeline candidate is a novel, modified-release, investigational formulation of budesonide, which is currently in Phase III clinical development for the treatment of primary IgAN. If approved, this will be the first drug specifically designed for primary IgAN. NPRC-019-2021
Based in Switzerland, Dialife is a global provider of high quality products, equipment and services for renal care. We offer a comprehensive range of devices and products for hemodialysis treatment, including dialysis machines, dialyzers, tubing sets, fistula needles, sodium bicarbonate cartridges, concentrates, disinfectants, endotoxin filters, on/off kits and more. We also provide turnkey solutions to set up hemodialysis centers, as well as transfer technology for the production of dialysis products.
Dr. Schär has been developing foods for people with special nutritional needs for almost 40 years. The lowprotein product line, FLAVIS, supports recommended medical nutrition therapy (MNT) for chronic kidney disease (CKD). At FLAVIS, we strive to facilitate dietary adherence in CKD patients in order to preserve kidney function and slow the progression towards renal replacement therapy (dialysis, kidney transplant).
In addition to being low in protein, FLAVIS products are low in sodium, phosphorus, and potassium. They are also rich in fiber and provide adequate calories to reduce risk of protein-energy-wasting (PEW).
Dustri-Verlag was founded in the late 40s of the last century. In 1965, the founder Karl Müller, a printer from Remscheid,
Germany, sold Dustri-Verlag to Dr. Karl Feistle, an ambitious young publisher. In 1999, Dustri-Verlag was taken over by
Karl’s sons Frank and Joerg Feistle, who have further expanded their father’s success. In 2003, the American office of
Dustri-Verlag was founded in Rockledge, FL, in order to improve contacts to its authors and readers.
For the past 50 years, Dustri-Verlag has been specializing in medical literature. The publisher’s oldest periodical was the
Medical Literature Adviser (MLA), offering information on the latest medical books to booksellers. The publication of
medical books, such as Facies dolorosa by Hans Kilian a famous German surgeon, also started soon. First published in
1971, Nieren- und Hochdruckkrankheiten (Renal and Hypertensive Diseases, founding editor R. Kluthe) was Dustri-
Verlag’s first journal. In 1973, the first English language journal followed: Clinical Nephrology (founding editor R. Kluthe),
soon well known as the “green journal”, was one of the first in its field. Since 1975, six new German-language journals
have been added to the program: Allergologie (Allergy), Atemwegs- und Lungenkrankenheiten (Airway and Lung
Diseases), Intensiv- und Notfallbehandlung (Critical Care), Verdauungskrankeiten (Gastroenterology), Prävention und
Rehabilitation (Prevention and Rehabilitation), and Dermatologie in Beruf und Umwelt (Occupational and Environmental
Dermatology). In addition to Clinical Nephrology, Dustri-Verlag also publishes three other international English-language
journals: Clinical Neuropathology, International Journal of Clinical Pharmacology and Therapeutics, and Trace Elements
A book program was launched in the 1970s, when the first yellow pocket books were published.
Today, Dustri-Verlag has a broad spectrum of books for many special fields of medicine – from large standard works to
highly specialized textbooks and useful patient guides.
Since 1990, Dustri-Verlag has been typesetting in its own studio. This has speeded up production and opened new
Dustri-Verlag has also tackled the challenges of digital revolution. All journal contents as well as the most important book
contents are offered online in electronic form. Many important libraries worldwide are connected to the Dustri database.
Furthermore, Dustri-Verlag has developed its own online submission system for a professional review process.
Dustri-Verlag particularly aims at supporting young doctors in publishing their research in journal articles or books,
ensuring that the content reaches a worldwide audience – on request also as open access article.
Everybody at Dustri-Verlag works with great personal commitment to satisfy our authors and readers.
Emodial is an Italian company that develops advanced solutions for the vascular access management in dialysis: the Silver line of pads, plasters and pockets for CVCs, peritoneal catheters and PICCs releasing silver ions with antibacterial and anti-inflammatory action, also available in procedural kits for start/end treatment and, upon completion of advanced dressings, the innovative waterproof pockets for catheter, for bath and shower.
Fluid-o-Tech is a leading global supplier of pumps and fluidic solutions in the medical sector. We can offer technical solutions for those devices where hydraulic parameters are critical for safety and performance requirements. Water quality in dialysis is crucial. Dialysate fluid is generated from RO systems, filtered, degassed and put in direct or indirect contact with the patient. Fluid-o-Tech pumps, valves, and sensors are key to precisely manage fluids within the dialysis systems.
We are the ideal partner to develop fluidic solutions with our Customers for use in medical devices.
Thanks to our experience, know-how, commitment and passion we bring patients hope for a better future.
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products and related devices. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases. We aim to create a future worth living for chronically and critically ill patients – worldwide and every day. We want to go a step further towards our vision by addressing the renal care continuum and with the help of critical care solutions and complementary assets.
Thereby, we rely on decades of experience in dialysis, our innovative research and our value-based care approach. We care for more than 346,500 dialysis patients. Their well-being always comes first. Our top priority is to offer them the best possible care.
The Swiss family owned company Geistlich Pharma develops and produces pharmaceutical and medical devices since 1851 with a worldwide distribution and provides valuable assistance in solving medical issues. Products such as the antimicrobial catheter lock solution TauroSept® for the prevention and treatment of CRBSIs, originate from the company’s own research facilities in Central Switzerland.
We are a science-led global healthcare company with a special purpose.
We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.
Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies.
Hansa Biopharma is a pioneering biopharmaceutical company and our mission is to develop innovative, lifesaving and life-changing treatments for patients with rare immunological conditions. Hansa has developed a first-in-class Immunoglobulin-G (IgG) antibody cleaving enzyme therapy, which can enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program exploring a broad range of conditions. Our pipeline is focussed on advancing the Company’s proprietary enzyme technology to develop the next generation of IgG-cleaving enzymes to enable repeat dosing in relapsing autoimmune diseases, chronic transplant rejection, oncology and gene therapy.
Herco Wassertechnik GmbH develops and offers complete water treatment solutions for dialysis applications since 1980.
Products are water softeners and filters for pre-treatment as well as reverse osmosis, ring main, bed head media panels, central concentrate distribution and mixing systems according to EN ISO 13485, TÜV approved. We also provide water treatment solutions for CSSD.
Herco Wassertechnik GmbH is an experienced manufacturer for water treatment equipment for medical, pharmaceutical and any kind of industrial applications. We provide standardized products and customized solutions.
Infomed, a major worldwide player on blood purification devices offers solutions for chronic and acute renal replacement (homecare and hospital environment) and for plasma therapies. Our products are adapted for adult and pediatric patients. DIMI, our home hemodialysis device, is the partner for a new life at home. DIMI was thought to offer the freedom to provide the optimal treatment conditions fulfilling the patient requirements. With more than 25 years of experience, Infomed is breaking new ground, creating devices beyond the state of the art.
International Society of Nephrology (ISN)
The International Society of Nephrology (ISN) is a global professional association dedicated to advancing kidney health worldwide since 1960 through education, grants, research, and advocacy. Through its members and global network of national and regional societies, the ISN engages 30,000 health professionals from across the globe to reduce the burden of kidney diseases and provide optimal health care for patients.
Join the ISN’s global community via our social media networks on Twitter (@ISNKidneyCare), Instagram, LinkedIn and Facebook.
Learn more about the ISN, its global professional network and extensive membership benefits at www.theisn.org.
ISPD – International Society for Peritoneal Dialysis
ISPD – International Society for Peritoneal Dialysis: The International Society for Peritoneal Dialysis works to increase the global uptake, promote quality practice, and achieve optimal outcomes of peritoneal dialysis through enhanced advocacy, research, and education, in order to improve the health and well-being of people living with end-stage kidney disease or suffering from acute kidney injury.
Established in 1989, Jafron engaged in research, production and marketing of biomaterials and medical devices. Jafron products focus on removal of toxins in blood for different diseases, covering critical care, nephrology, hepatology, and immunological diseases, etc. With nearly 20-years clinical experience, Jafron hemoperfusion treatments have been adopted in over 4500 hospitals in 50 countries, with about 3 million cases of clinical application annually. Listed on ChiNext in 2016, Jafron is a now leading enterprise in Chinese blood purification industry. In 2020, as a comprehensive adsorption solution provider，Jafron will keep exploring other novel medical fields to realize the vision of “Health Technology for a Better World”.
A modern medical technology company
Joline is a global acting company located in the southern part of Germany. For more than a decade Joline has built on a long tradition in the development and production of medical products under the highest “Made in Germany” quality standards. Advanced production technology and medical expertise ensure production consistency and reliabilty.
Focused on minimally invasive therapies Joline is a leading provider of catheters, balloon catheters and stents. All Joline products are CE (EN ISO 13485:2016) marked and have been developed and produced exclusively in Germany. Excellent customer relations are essential for our success.
Every individual has the responsibility to meet the target.
We are one team
We act with responsibility
We think globally, while taking care of our region.
Teamwork is essential
We respect our colleagues, customers, patients and suppliers
We are open and honest
We respect the la wand regulations
Orientation on business success
We follow a clear strategy and targets
We are focused on priorities and do our best
We want to be the leader in our business: Think big!
Mutual respect, trust and honesty are the bases of a successful cooperation
We see our customers and suppliers as competent partners in an active cooperation
We create “customer benefits”
We create a positive working climate that is based upon tolerance and equal possibilities.
We are solution oriented and focused on business success.
We focus our actions on the clearly defined Joline strategy and resulting targets
We simplify and optimise our daily work, wherever possible.
Our working style is goal-oriented. We do not spend time on activities that have no added value or target driven benefit.
We do not transfer our own responsibility to others.
We aspire to high quality in all our processes and products
We highly value personal abilities and personal responsibilities.
We are convinced that flexibility and the motivation of each individual person guarantees our success
We provide an environment, within which our people have the possibility to fulfill high expectations and challenging goals
We want to learn from our successes but also from our mistakes.
Journal of Kidney Care (JKC)
The Journal of Kidney Care (JKC) is the essential bi-monthly double-blind peer-reviewed publication for all members of the multidisciplinary renal team. It covers all the key clinical areas of renal medicine, such as dialysis, transplantation, diabetes, anaemia, pharmacy, vascular access and nutrition. Every issue of the journal will have a clinical focus on one of these key aspects of kidney care. Formerly Journal of Renal Nursing, JKC was relaunched to reflect the multidisciplinary nature of kidney care and the wide range of the journal’s content. The JKC is received exclusively through paid subscriptions to a readership of 7,500 dedicated renal specialists. It is also the official journal for both the British Renal Society (BRS) and the Association of Nephrology Nurses UK (ANN UK) for their members. It is the leading, most targeted clinical platform for commercial awareness, promotion and education in the renal market.
Japanese Society of Nephrology (JSN)
The mission of the JSN is to contribute to society and respond to our public mandate through research and the dissemination of knowledge related to nephrology. In order to accomplish this mission, we engage in a wide range of activities, including research in the field of nephrology, developing human resources, providing for lifelong education, giving back and disseminating knowledge and skills to Japanese citizens, and contributing to the public health and welfare of our nation.
Karger Publishers is a publishing house whose titles in the field of nephrology include several scientific journals as well as the renowned book series Contributions to Nephrology. All publications are accessible online, with full-text search of articles, pay-per-view options and many other services. Founded 130 years ago, the Swiss-based family-owned publishing house combines highly sophisticated production technology with customized services for its authors, editors and readers.
KDIGO is an independent foundation incorporated in Belgium accountable to the public and the patients it serves. Its mission is to improve the care and outcomes of kidney disease patients worldwide through the development and implementation of global clinical practice guidelines. The KDIGO Global Network promotes awareness, dissemination, adoption and clinical integration of KDIGO Clinical Practice Guidelines. The Global Network is composed of volunteers from around the world who work to implement KDIGO guidelines in their respective countries or regions.
MediBeacon is a medical technology company specializing in advances of fluorescent tracer agents and transdermal measurement with a focus on delivering actionable organ function measurements. In preclinical research the Transdermal Mini GFR Monitor system tracks Glomerular Filtration Rate (GFR) without restraining the animal. The system obviates the need for blood sampling, urine collection, and laboratory assays thus enabling superior trial design. The result is enhanced kidney therapeutic assessment, nephrotoxicity evaluation and fundamental understanding of kidney function in animals.
As a global leader in medical technology, services and solutions, Medtronic improves the health and lives of millions of people each year. We believe our deep clinical, therapeutic and economic expertise can help address the complex challenges—such as rising costs, aging populations, and the burden of chronic disease—faced by families and healthcare systems today. We can’t do it alone. That’s why we’re committed to partnering in new ways and developing powerful solutions that deliver better patient outcomes.
Founded in 1949 as a medical repair company, we’re now among the world’s largest medical technology, services and solutions companies, employing more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries. Join us in our commitment to take healthcare Further, Together.
MedXL Europe BV is a Dutch based medical device company with a key focus on the area of Vascular Access and automated systems for the prepration of medication in syringes. Providing market leading solutions for both central venous catheter and AV fistula access. We are committed to helping patients and healthcare professionals to maintain vascular access patency whilst simultaneously reducing catheter related blood stream infections (CRBSI).
MedXL manufactures a diverse line of prefilled syringes including sterile water syringes, normal saline syringes and anticoagulant prefilled syringes such sodium citrate prefills. Prefilled syringes help to improve healthcare professionals’ efficiency by offering a ready to use product but more importantly help to reduce medication errors. Prefilled syringes are practical, reliable and secure. MedXL plans to continue expanding this market and to roll out new products through investments in research and development.
NephroCan is a Canadian company committed to improving the quality of life for patients with End Stage Renal Disease (ESRD). As a trusted partner in the field, we strive to offer the A to Z of hemodialysis consumables, equipment and machinery. For over a decade, we at NephroCan have been providing research and development for companies specializing in the dialysis industry, catering to patients globally. We consistently strive to offer the highest quality hemodialysis products. Our promise is to improve therapy methods year after year.
NIKKISO, a pioneer in Renal Replacement Therapies, strives to advance complex medical technologies that optimise patient care in End-stage Renal and Critical Care areas. Through our commitment to improving clinical efficiency and patient QoL, Nikkiso has built a global reputation for unparalleled quality and innovation.
Look out for NIKKISO’s latest innovations on our company page. Aeroclear, our novel air disinfection device, DBB-EXA ES, our dialysis equipment for standard HD treatments and PureADJUST, our versatile hemoperfusion pump await you, along with information about DBB-EXA and Aquarius+!
Nipro Renal Care
Nipro Medical Europe is part of Nipro Corporation Japan, a leading global healthcare company established in 1954. With over 33.000 employees worldwide, Nipro serves the Medical Device, Pharmaceutical, and Pharmaceutical Packaging industries.
Nipro is a global market leader with over 5 decades providing renal solutions for dialysis and dialysis-related treatment. We specialize in developing dialysis machines, water treatment systems, and a comprehensive portfolio of disposable medical equipment.
In order to address the needs of patients, healthcare professionals, and procurement managers alike, Nipro is driven by innovation and patient safety to offer the highest quality products that optimize time, effort, and costs.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world.
At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic diseases. Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic diseases: haemophilia, growth disorders and obesity, chronic kidney disease, cardiovascular disease and NASH. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries.
Oxford University Press is a leading publisher in nephrology journals, books and online products. Our worldwide publishing furthers the University’s objectives of excellence in scholarship, research, and education. Visit our profile to discover the latest content and news from Nephrology Dialysis Transplantation (ndt) and Clinical Kidney Journal (ckj), the official journals of the ERA-EDTA. You can also browse our extensive collection of books, available to buy with an exclusive 20% conference discount and 35% discount for ERA-EDTA members.
Leader in home hemodialysis, Physidia is a French company specialized in developing, manufacturing and commercializing an innovative equipment and disposables for delivering frequent hemodialysis treatment. Physidia’s innovations are based on several technological breaking points, offering a robust, portable and connected device, whilst ensuring a performing treatment in total autonomy. Created by an expert team, Physidia’s S3 monitor has been specifically developed to respond to the needs of simplicity and safety of ESRD patients in home hemodialysis. Physidia is present today in 14 countries, operating directly in France and The United Kingdom and through distributor partners in the rest of Europe.
PromarkerD is the world’s leading predictive test for diabetic kidney disease, the only test capable of predicting onset up to 4 years before clinical symptoms appear.
Diabetic kidney disease (DKD) is the leading cause of chronic and end-stage kidney disease worldwide. Most people with DKD do not have symptoms.
Tested on over 5,000 patients in 4-year clinical studies, patients designated as high-risk by a PromarkerD test are 13.5 times more likely than low-risk to develop DKD. Doctors can then prescribe an early therapeutic treatment to slow or stop the onset of disease.
ELISA test available in Europe.
Prevention is better than cure – transform clinical outcomes.
Reata Pharmaceuticals, Inc.
Our scientific mission is to identify, develop, and commercialize small molecule therapeutics with novel mechanisms of action for the treatment of severe life-threatening diseases that have few or no approved therapies. We focus on molecular pathways that regulate cellular metabolism, inflammation, and the cellular response to injury.
Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, rare blood disorders, neurology, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
In 2000, TauroPharm GmbH was founded as a German company specialising in medical devices with antimicrobial, antibiofilm and antiocclusive efficacy.
Based on its innovative products, we aim to develop more effective ways to prevent catheter-associated complications – ranging from blood clotting to fatal infections. Throughout this process, improving the patient’s quality of life remains our top priority.
Since there is an urgent need for our products, especially in light of the steadily increasing number of antibiotics-resistant pathogens, TauroLock is recommended in interdisciplinary national and international guidelines. All products have been investigated in independent scientific studies with excellent study results.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Our Specialty Brands segment includes branded medicines and the Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing.
Therakos is a specialty brand of Mallinckrodt that focuses on the delivery of ECP Immunomodulation. The THERAKOSTM CELLEX™ Photopheresis System is the world’s only fully integrated and validated ECP system and is used by over 300 treatment centres in over 30 countries worldwide.
Beyond the THERAKOS™ CELLEX™ Photopheresis System, we offer a comprehensive range of support services to help enable healthcare professionals (HCPs) to deliver optimised ECP immunomodulation to patients. Therakos have been crafting ECP solutions (products, services and education) since 1987.
Toray Medical Co., Ltd. is a member company of Toray Group, specializing in healthcare field business.
Toray is a leading manufacturer of synthetic fibers and dedicated to the development of dialysis
products under its corporate slogan, “Innovation by Chemistry”. Toray supports high quality and
advanced medical care with bio-compatible polymethylmethacrylate dialyzer “FILTRYZER”, high flux
polysulfone dialyzer “TORAYSULFONE”, “TORAYLIGHT” and dialysis machine.
At Travere Therapeutics we are in rare for life. We come together every day to help patients, families and caregivers as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent and we work with the rare disease community to identify, develop and deliver life-changing therapies. We continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.
We are focused on discovering and researching methods aimed at treating the underlying cause of APOL1-mediated kidney diseases.
The genetic link between APOL1 gene variants and severe kidney diseases was only identified in 2010.
That insight led our team to work to invent new investigational medicines to potentially target the underlying cause of APOL1-mediated kidney diseases, including FSGS.
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.
Werfen is a global leader in in vitro diagnostics (IVD) in the specialties of Hemostasis, Acute Care Diagnostics Care and Autoimmunity. Our core business is dedicated to R&D, manufacturing and distribution of diagnostic systems for hospitals and clinical laboratories. Our other areas of expertise include Original Equipment Manufacturing, IVD & Clinical Software, Clinical Chemistry, Infusion Therapy, and Medical Devices Distribution. We operate directly in over 30 countries and in more than 100 territories through distributors.
Glycated Albumin (GA) is an important part of Werfen Clinical Chemistry portfolio. GA is a mid-term glycaemic marker. It is a unique marker capable to address and evaluate glycaemic status in DKD patients, highlighting therapy adherence and success or changes in glycaemic profiles.
These accesses are for Visitors wishing to enter the exhibition only.
The cost for and individual access is:
EUR 150.00, plus VAT if applicable if pre-ordered by May 7, 2021
EUR 200.00, plus VAT if applicable if booked after May 7, 2021.
These accesses do not allow participation in the scientific sessions or any other scientific activities, except the Industry Symposia. Certification points cannot be collected with the exhibitor access.